Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vaxil BioTherapeutics (accquired in 2016)

Vaxil BioTherapeutics (accquired in 2016)
2006 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
$4.6M LATEST DEAL AMOUNT
Description

Provider of cancer treatment services. The company caters to the healthcare industry and develops vaccines for cancer and tuberculosis.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Services
Other Industries
Other Pharmaceuticals and Biotechnology
Parent Company
Primary Office
  • P.O.Box 4058
  • Nes-Ziona 7414001
  • Israel

+972 00-000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vaxil BioTherapeutics (accquired in 2016)’s full profile, request a free trial.

Vaxil BioTherapeutics (accquired in 2016) Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 29-Feb-2016 $4.6M 00.00 Completed Generating Revenue
2. Reverse Merger 25-Jul-2012 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Vaxil BioTherapeutics (accquired in 2016) Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 000 00000 Angel-Backed Des Moines, IA 00.000 0000000000 00.000
To view this company’s complete list of competitors, request access »

Vaxil BioTherapeutics (accquired in 2016) Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Silver Cloud Ventures Venture Capital Minority 000 0000 000000 0

Vaxil BioTherapeutics (accquired in 2016) Executive Team (1)

Name Title Board
Seat
Contact
Info
Julian Levy Co-Founder, Chief Financial Officer and President